Morgan Stanley’s EPIRUS BIOPHARMACEUTICALS INC COM EPRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q3
Sell
-1,074
Closed 6775
2016
Q2
$0 Buy
1,074
+841
+361% +$1.35K ﹤0.01% 7007
2016
Q1
$1K Buy
233
+83
+55% +$233 ﹤0.01% 6536
2015
Q4
$0 Sell
150
-1,500
-91% -$6.76K ﹤0.01% 7121
2015
Q3
$7K Sell
1,650
-166
-9% -$975 ﹤0.01% 6344
2015
Q2
$11K Sell
1,816
-2,512
-58% -$17.1K ﹤0.01% 6290
2015
Q1
$38K Buy
4,328
+545
+14% +$4.38K ﹤0.01% 5890
2014
Q4
$22K Buy
3,783
+2,770
+273% +$14.5K ﹤0.01% 6031
2014
Q3
$7K Buy
+1,013
New +$8.76K ﹤0.01% 6288

Other funds holding EPRS

Morgan Stanley's EPRS Position: Q3 2016 in Review

Morgan Stanley sold out of EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) in Q3 2016, closing a stake of 1,074 shares.

Morgan Stanley first reported a position in EPRS in Q3 2014 and held it in 8 quarters. The position peaked at $38K in Q1 2015. 3 funds tracked by Wall St. Rank hold EPRS as of Q3 2016.

  • Morgan Stanley reported no remaining EPIRUS BIOPHARMACEUTICALS INC COM position as of Q3 2016 after selling out during the quarter.
  • Morgan Stanley sold 1,074 EPIRUS BIOPHARMACEUTICALS INC COM shares in Q3 2016.
  • Morgan Stanley first reported a position in EPIRUS BIOPHARMACEUTICALS INC COM in Q3 2014 and held it in 8 quarters.
  • Morgan Stanley's EPIRUS BIOPHARMACEUTICALS INC COM position peaked at $38K in Q1 2015.
  • 3 funds tracked by Wall St. Rank held EPIRUS BIOPHARMACEUTICALS INC COM as of Q3 2016.

Based on Morgan Stanley's 13F filing for Q3 2016, filed 10 Nov 2016.